Companies: 10,795·Total market cap: $144.5T
Liquidia Corporation

Liquidia Corporation

LQDANASDAQHealthcare● Active
$63.66
+$1.81(+2.93%)
Market Cap$5.7B
P/E Ratio
52W High$66.775
52W Low$11.85
Overview

Liquidia Corporation (LQDA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

lqda · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Liquidia Corporation (LQDA) measures how much investors pay for each dollar of the company's trailing earnings. LQDA's current PE ratio of 251.75x is calculated by dividing its stock price of $63.66 by its TTM earnings per share of $0.25.

251.75x
P/E Ratio (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
11.18x
FY2027 est. EPS $5.70
Based on 5 analysts
EPS (TTM)
$0.25
TTM · diluted EPS
PEG Ratio
1.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Liquidia Corporation SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2016 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Liquidia Corporation
Liquidia CorporationYou
LQDA
$5.7B251.75x$0.25
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
AGIO
$1.6BN/A-$7.12
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
COGT
$5.3BN/A-$4.87
Denali Therapeutics Inc.
Denali Therapeutics Inc.
DNLI
$3.1BN/A-$2.92
89bio, Inc.
89bio, Inc.
ETNB
$2.2BN/A-$3.51
Galapagos N.V.
Galapagos N.V.
GLPG
$1.8B5.74x$4.85
Structure Therapeutics Inc.
Structure Therapeutics Inc.
GPCR
$2.1BN/A-$2.39

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 10 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.80
2024-12-31
FY2024
$-1.66
2023-12-31
FY2023
$-1.21
2022-12-31
FY2022
$-0.67
2021-12-31
FY2021
$-0.70
2020-12-31
FY2020
$-1.76
2019-12-31
FY2019
$-2.57
2018-12-31
FY2018
$-7.42
2017-12-31
FY2017
$-3.40
2016-12-31
FY2016
$-1.86

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Liquidia Corporation (LQDA) measures how much investors pay for each dollar of the company's trailing earnings. LQDA's current PE ratio of 251.75x is calculated by dividing its stock price of $63.66 by its TTM earnings per share of $0.25.

PE Ratio = Stock Price ÷ EPS (TTM)
= $63.66 ÷ $0.25 = 251.75x
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

LQDA pe ratio · 6 questions

LQDA's current PE ratio is 251.75x as of 2026-06-08, based on a stock price of $63.66 and TTM EPS of $0.25. Data sourced from Financial Modeling Prep via LQDA's SEC 10-K and 10-Q filings.

LQDA PE ratioWhat is LQDA PE ratioCurrent PE ratio of LQDALQDA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Liquidia Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08